Advertisement

InVivo Therapeutics Holdings Corp. (OTCBB: NVIV), which develops technologies for treatment of spinal cord injuries, reported a net loss of $34.7 million, or $0.67 per diluted share, for the year ending Dec. 31, 2011.

SOURCE

Advertisement
Advertisement